Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). BioLife Solutions's share price for the quarter that ended in Mar. 2026 was €16.2. BioLife Solutions's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 48.83 Mil. Therefore, BioLife Solutions's market cap for the quarter that ended in Mar. 2026 was €790.97 Mil.
BioLife Solutions's quarterly market cap
increased
from Sep. 2025 (€988.10 Mil) to Dec. 2025 (€1,021.82 Mil) but then
declined
from Dec. 2025 (€1,021.82 Mil) to Mar. 2026 (€790.97 Mil).
BioLife Solutions's annual market cap
increased
from Dec. 2023 (€672.99 Mil) to Dec. 2024 (€1,182.06 Mil) but then
declined
from Dec. 2024 (€1,182.06 Mil) to Dec. 2025 (€1,021.82 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioLife Solutions's Enterprise Value for Today is €1,229.40 Mil.
BioLife Solutions (FRA:BJX1) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BioLife Solutions Market Cap Related Terms
BioLife Solutions Market Cap Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BJX1 vs STAA, ATRC, KMTS: Market Cap Comparison
For the Medical Instruments & Supplies subindustry, BioLife Solutions's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Market Cap distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BioLife Solutions's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLife Solutions (FRA:BJX1) has a Market Cap of €1,287.54 Mil as of Jul. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioLife Solutions and its competitors. According to the industry distribution chart, BioLife Solutions ranks #133 out of 863 companies in the Medical Devices & Instruments industry, placing it in the top 15.4%.
Is BioLife Solutions' Market Cap too high?
BioLife Solutions' current Market Cap is €1,287.54 Mil. Based on the distribution chart, BioLife Solutions ranks #133 out of 863 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, BioLife Solutions has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Market Cap compare to STAA and ATRC?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #133 out of 863 companies for Market Cap. This places BioLife Solutions in the top 15% of its industry — outperforming the majority of peers. The industry median Market Cap is 114.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 114.85, based on 863 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on BioLife Solutions and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 114.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current Market Cap is €1,287.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (FRA:BJX1) is currently considered Fairly Valued. The stock's GF Value™ is €25.92, compared to a current price of €26.80 — trading 3.4% above its estimated fair value. The current Market Cap is €1,287.54 Mil. BioLife Solutions' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For BioLife Solutions (FRA:BJX1), the current Market Cap is €1,287.54 Mil as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (FRA:BJX1) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued.
The current stock price of €26.80 is trading 3.4% above its estimated GF Value™ of €25.92.
GuruFocus considers BioLife Solutions to be Fairly Valued.
Key valuation signals for FRA:BJX1:
Market Cap: €1,287.54 Mil
GF Value™: €25.92 vs. price of €26.80 (3.4% above fair value)
No single metric tells the full story. See the FRA:BJX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
71GF Score
Get the complete analysis for FRA:BJX1
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BJX1 has been successfully added to your 
